Colistin‐Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of BiofilmPseudomonas aeruginosa

2010/10/13 by Gloria Herrmann, Liang Yang, Hong Wu +7 · 27 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Bacterial biofilms and quorum sensing #Antibiotic Resistance in Bacteria #Cystic Fibrosis Research Advances

paper · doi:10.1086/656788

Abstract

BACKGROUND: Antibiotic combination therapy might be more efficient than single antibiotics to combat Pseudomonas aeruginosa biofilms in the airways of patients with cystic fibrosis. We tested the ability of colistin sulphate-tobramycin combinations and single antibiotics to kill P. aeruginosa biofilms. METHODS: P. aeruginosa biofilms were generated in vitro and in rat lungs. In a pilot study, 5 patients with cystic fibrosis inhaled colistin and then tobramycin for 4 weeks. The changes in P. aeruginosa counts and lung function were assessed before and after therapy. RESULTS: Antibiotic combination therapy significantly reduced the number of P. aeruginosa cells in P. aeruginosa biofilm models in vitro. When rats were challenged with 1 x 10(7) cfu of P. aeruginosa, which was embedded in alginate beads, mortality rates, lung pathologic findings, and bacterial colony-forming unit counts were significantly lower after 7 days in animals receiving antibiotic combination than in animals receiving single antibiotics. In patients with cystic fibrosis, inhaled colistin-tobramycin was well tolerated and resulted in a mean decrease of 2.52 + /- 2.5 log(10) cfu of P. aeruginosa per milliliter of sputum (P = .027). Measurements of forced expiratory volume in 1 s, obtained both before and after the study, did not differ significantly. CONCLUSION: Colistin-tobramycin combinations are more efficient than respective single antibiotics for killing P. aeruginosa in biofilms in vitro, and they significantly reduced P. aeruginosa cell counts in a rat lung infection model and in patients with cystic fibrosis.

Cited by

• New insights into the inhibitory roles and mechanisms of D-amino acids in bacterial biofilms in medicine, industry, and agriculture
• Antibiotic treatment of biofilm infections
• Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. [europepmc]
• Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. [europepmc]
• Immune mediators of sea-cucumber Holothuria tubulosa (Echinodermata) as source of novel antimicrobial and anti-staphylococcal biofilm agents. [europepmc]
• Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms. [europepmc]
• C-di-GMP regulates Pseudomonas aeruginosa stress response to tellurite during both planktonic and biofilm modes of growth. [europepmc]
• In Vivo Efficacy of Antimicrobials against Biofilm-Producing Pseudomonas aeruginosa. [europepmc]
• Autoinducer-2 regulates Pseudomonas aeruginosa PAO1 biofilm formation and virulence production in a dose-dependent manner. [europepmc]
• Antibiofilm Peptides: Potential as Broad-Spectrum Agents. [europepmc]
• Control of Biofilm Formation: Antibiotics and Beyond. [europepmc]
• Synergistic combinations of polymyxins. [europepmc]
• Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. [europepmc]
• Individual and Combined Effects of Engineered Peptides and Antibiotics on Pseudomonas aeruginosa Biofilms. [europepmc]
• The Consequences of Being in an Infectious Biofilm: Microenvironmental Conditions Governing Antibiotic Tolerance. [europepmc]
• Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa biofilms. [europepmc]
• Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics. [europepmc]
• Emerging therapies against infections with Pseudomonas aeruginosa . [europepmc]
• Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. [europepmc]
• Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome. [europepmc]
• Antimicrobial Peptides Derived From Insects Offer a Novel Therapeutic Option to Combat Biofilm: A Review. [europepmc]
• The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings. [europepmc]
• Antimicrobial Peptides as an Alternative for the Eradication of Bacterial Biofilms of Multi-Drug Resistant Bacteria. [europepmc]
• An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents. [europepmc]
• Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. [europepmc]
• Synergistic action of antimicrobial peptides and antibiotics: current understanding and future directions. [europepmc]
• The Global Challenge of Antimicrobial Resistance: Mechanisms, Case Studies, and Mitigation Approaches. [europepmc]

Related

• In vitro synergy of antibiotic combinations against planktonic and biofilm Pseudomonas aeruginosa
• The cystic fibrosis pathogen Achromobacter xylosoxidans inhibits biofilm formation of Pseudomonas aeruginosa
• Interspecies interactions alter the antibiotic sensitivity of Pseudomonas aeruginosa
• Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections
• Colistin-resistant Pseudomonas aeruginosa clinical strains with defective biofilm formation